Supernus Pharmaceuticals, Inc. (SUPN)

From the record

Supernus Pharmaceuticals, Inc.'s filings since 2017 show 10 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, 3 times, the latest 2026-11-02); a late-report notice (Form NT 10-K or NT 10-Q, 7 times, the latest 2023-03-02) (its current reports).

From the record

Supernus Pharmaceuticals, Inc.'s 8 filed years say what it did: revenue went from $409 million in fiscal 2018 to $719 million in fiscal 2025, up 8.4% a year; it rose in 5 of 7 years; the deepest fall was 9% from fiscal 2022 to fiscal 2023; net income was positive in 7 of 8 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Supernus Pharmaceuticals, Inc.'s diluted share count shrank about 2.9% a year, and dividends and buybacks returned about 0% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 20 sales (13 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-11-04 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Supernus Pharmaceuticals, Inc. lost about 4 cents for every dollar of shareholders' money, and gross profitability: its products earned about 44 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 27 cents per dollar of assets, and net share issuance: its share count grew 0.9% over the year (the filed statements).

From the record

Supernus Pharmaceuticals, Inc.'s standing among 315 graded names in its industry family: revenue of $719 million in fiscal 2025 ranks in the top 16% by size; a net margin of -5.4% ranks in the top 27%; revenue growth of 2.5% a year over the last 3 filed years ranks in the bottom 42% (its annual reports).

From the record

Supernus Pharmaceuticals, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Khattar, Jack A. (President, CEO, as filed), filing under that title since 2012-04-30, 14.5 years (top 6% of its family); the 11 officers and directors filing in the last fifteen months have been on the record a median of 8.4 years (top 18%); 7 officer or director changes were reported on Form 8-K since 2023-11-13, against the 11 people in charge now (bottom 30%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Supernus Pharmaceuticals, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $128 million against no long-term debt tagged leaves 8.8% of its assets as net cash, bottom 24% of its family; cash from operations less capital spending is 6.4% of revenue (top 24%); a gross margin of 89.6% (top 15%); research spending of 14.8% of revenue (bottom 18%) (its annual report).

From the record

Supernus Pharmaceuticals, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 2.5% a year over the last three filed years against 8.4% over all 8, slowing (bottom 42% of its family); the newest year grew 8.6% (top 48%); research spending grew 12.5% a year (top 35%); capital spending grew 48.1% a year (top 17%) (its annual reports). Supernus Pharmaceuticals, Inc. reported 9 product lines in fiscal 2025: Qelbree at $305 million (42%), GOCOVRI at $147 million (20%), Collaboration Revenue at $53 million (7%), and 6 more; 3 of 7 grew against the year before (its annual report).

From the record

Supernus Pharmaceuticals, Inc.'s newest year against its own record: revenue of $719 million in fiscal 2025 came in 9.1% above the $659 million its prior three years' pace pointed to (top 34% of its family); net income of $39 million against a prior three-year average of $45 million (bottom 9%); a net margin of -5.4% against 6.8% before (bottom 28%) (its annual reports).